|
| Home : Connect Biopharmaceuticals Advances CBP-201, a Novel Monoclonal Antibody Against IL-4Rα, Into Clinical Development |
|
Apr 24
2018 |
Connect Biopharmaceuticals Advances CBP-201, a Novel Monoclonal Antibody Against IL-4Rα, Into Clinical Development |
|
TAICANG, China, April 24, 2018 /PRNewswire/ -- Connect Biopharmaceuticals, Ltd. today announced that it has submitted an application in Australia to begin a phase 1 clinical trial to evaluate CBP-201, the company's monoclonal antibody candidate for allergic inflammation.
The planned... |
|
|
|
| Source:https://www.prnewswire.com/news-releases/connect-biopharmaceuticals-advances-cbp-201-a-novel-monoclonal-antibody-against-il-4r-into-clinical-development-300635095.html |
| |
|
Related News
|
» The First Maritime Silk Road ECI International Innovation Festival Lands In Quanzhou
» Volvo Group - The First Quarter 2018
|
|
|
